Study Confirms Hydroxychloroquine Reduces Covid Risk
Oct 8, 2024 14:35:57 GMT -5
Post by schwartzie on Oct 8, 2024 14:35:57 GMT -5
Study Confirms Hydroxychloroquine Reduces Covid Risk
Frank Bergman
October 8, 2024 - 12:23 pm
Another study has emerged to confirm that the antiviral drug hydroxychloroquine can be used as a safe and effective measure against COVID-19.
The latest study found that people who are vulnerable to Covid can reduce the risk of the virus by taking a course of hydroxychloroquine (HCQ).
As Slay News previously reported, a study conducted last year also found that HCQ greatly reduces the risk of death in seriously ill patients.
More recently, an Oxford University study confirmed last month that hydroxychloroquine is a “safe and effective” treatment for anyone infected with Covid.
However, despite previous reports of the drug’s success, guidelines around the world recommend against the use of HCQ for COVID-19.
It has widely been rumored that HCQ was suppressed to protect pharmaceutical industry interests as the cheap and widely available drug showed great promise in treating Covid before mRNA “vaccines” were rolled out for public use in early 2021.
In addition, President Donald Trump touted HCQ as a potential treatment for Covid, which led to a global smear campaign against the drug by the liberal corporate media.
The latest study, conducted by experts from the First Affiliated Hospital at Fujian Medical University in China, found that people at risk from the virus can take a 5-8 week course HCQ to significantly reduce the impact of catching Covid.
Further, the researchers found that a long course of hydroxychloroquine carries a very low risk of adverse events.
In fact, the study found that the drug is far safer and more effective than high-risk Covid mRNA “vaccines.”
The new study’s paper was published October 4, 2024, in Expert Review of Anti-infective Therapy, a Taylor and Francis journal.
The researchers sought to better understand both the safety and efficacy of varying doses and treatment durations of hydroxychloroquine for COVID-19 prevention.
As part of this systematic and networked meta-analysis, the team of researchers, led by Wang Hang and Zhan Zhikun from the academic medical center’s Department of Pharmacy, tapped into common medical literature databases, including PubMed, Web of Science, Cochrane Library, EMBASE, Medline, and ClinicalTrials.gov.
The study specifically analyzed information on the use of various doses of hydroxychloroquine for COVID-19 prevention.
The study included an analysis of 20 randomized controlled trials totaling 12,372 patients.
Hang and colleagues report that the recent Oxford University study aligned with their findings showing that HCQ successfully treats Covid patients.
Interestingly, however, they confirmed that hydroxychloroquine was successful as a safe preventative measure against the virus.
The researcher notes that, in a “subgroup receiving a daily dose of 200-400 mg” for “a treatment duration of 5-8 weeks,” there were “statistically significant reductions in SARS-CoV-2 positivity.”
The authors revealed the most effective intervention was a 200-400 mg dose for 5-8 weeks.
The recent studies’ findings show that, despite all the fearmongering about HCQ, the drug could have been used as a safe, well-tolerated means of at least moderate protection against SARS-CoV-2, the virus that causes Covid.
Many lives could have been saved had this outcome come sooner.
However, the authors of the Oxford study acknowledge that it is “unlikely” that HCQ would be used extensively to protect against COVID-19 moving forward.
They note that the drugs “could have been deployed with benefit earlier, and they might have value in future pandemics.”
These findings are a major turnaround from what was incredible politicization involving this drug and COVID-19.
The Oxford researchers concluded that “trials should be facilitated and protected so that evidence is generated rapidly and evidence-based policies can be implemented without delay to allow timely interventions.”
Unfortunately, people were left to die during the pandemic because doctors were banned from treating patients with the politicized drug.
link
Frank Bergman
October 8, 2024 - 12:23 pm
Another study has emerged to confirm that the antiviral drug hydroxychloroquine can be used as a safe and effective measure against COVID-19.
The latest study found that people who are vulnerable to Covid can reduce the risk of the virus by taking a course of hydroxychloroquine (HCQ).
As Slay News previously reported, a study conducted last year also found that HCQ greatly reduces the risk of death in seriously ill patients.
More recently, an Oxford University study confirmed last month that hydroxychloroquine is a “safe and effective” treatment for anyone infected with Covid.
However, despite previous reports of the drug’s success, guidelines around the world recommend against the use of HCQ for COVID-19.
It has widely been rumored that HCQ was suppressed to protect pharmaceutical industry interests as the cheap and widely available drug showed great promise in treating Covid before mRNA “vaccines” were rolled out for public use in early 2021.
In addition, President Donald Trump touted HCQ as a potential treatment for Covid, which led to a global smear campaign against the drug by the liberal corporate media.
The latest study, conducted by experts from the First Affiliated Hospital at Fujian Medical University in China, found that people at risk from the virus can take a 5-8 week course HCQ to significantly reduce the impact of catching Covid.
Further, the researchers found that a long course of hydroxychloroquine carries a very low risk of adverse events.
In fact, the study found that the drug is far safer and more effective than high-risk Covid mRNA “vaccines.”
The new study’s paper was published October 4, 2024, in Expert Review of Anti-infective Therapy, a Taylor and Francis journal.
The researchers sought to better understand both the safety and efficacy of varying doses and treatment durations of hydroxychloroquine for COVID-19 prevention.
As part of this systematic and networked meta-analysis, the team of researchers, led by Wang Hang and Zhan Zhikun from the academic medical center’s Department of Pharmacy, tapped into common medical literature databases, including PubMed, Web of Science, Cochrane Library, EMBASE, Medline, and ClinicalTrials.gov.
The study specifically analyzed information on the use of various doses of hydroxychloroquine for COVID-19 prevention.
The study included an analysis of 20 randomized controlled trials totaling 12,372 patients.
Hang and colleagues report that the recent Oxford University study aligned with their findings showing that HCQ successfully treats Covid patients.
Interestingly, however, they confirmed that hydroxychloroquine was successful as a safe preventative measure against the virus.
The researcher notes that, in a “subgroup receiving a daily dose of 200-400 mg” for “a treatment duration of 5-8 weeks,” there were “statistically significant reductions in SARS-CoV-2 positivity.”
The authors revealed the most effective intervention was a 200-400 mg dose for 5-8 weeks.
The recent studies’ findings show that, despite all the fearmongering about HCQ, the drug could have been used as a safe, well-tolerated means of at least moderate protection against SARS-CoV-2, the virus that causes Covid.
Many lives could have been saved had this outcome come sooner.
However, the authors of the Oxford study acknowledge that it is “unlikely” that HCQ would be used extensively to protect against COVID-19 moving forward.
They note that the drugs “could have been deployed with benefit earlier, and they might have value in future pandemics.”
These findings are a major turnaround from what was incredible politicization involving this drug and COVID-19.
The Oxford researchers concluded that “trials should be facilitated and protected so that evidence is generated rapidly and evidence-based policies can be implemented without delay to allow timely interventions.”
Unfortunately, people were left to die during the pandemic because doctors were banned from treating patients with the politicized drug.
link
